Šárka Pavlová

1.4k citations
42 papers · 854 indexed · h-index 15
Topics
Chronic Lymphocytic Leukemia Research (25 papers)Cancer-related Molecular Pathways (16 papers)Lymphoma Diagnosis and Treatment (10 papers)
Partner nations
CzechiaGermanySweden

In The Last Decade

Šárka Pavlová

40 papers receiving 846 citations

Peers

Šárka Pavlová
Comparison fields: 5 of 64
  • Molecular Biology 443
  • Genetics 342
  • Oncology 258
  • Pathology and Forensic Medicine 190
  • Immunology 176
Replace Dominique Vaur with:
Dominique Vaur France
Elisabeth Oelmann Germany
Fernando Pardal Portugal
Ludger Sellmann Germany
Carolina Vicente‐Dueñas Spain
Mattias Berglund Sweden
Anthony Laugé France
Iracema Nayach Spain
Meena Kanduri Sweden
Alison M. McCaig United Kingdom
Šárka Pavlová relative to Dominique Vaur France Dominique Vaur's profile →
Citations per field
00.5×1.6×
Dominique Vaur · 1×
Citations per year

Countries citing papers authored by Šárka Pavlová

Since Specialization
Citations

This map shows the geographic impact of Šárka Pavlová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Šárka Pavlová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Šárka Pavlová more than expected).

Fields of papers citing papers by Šárka Pavlová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Šárka Pavlová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Šárka Pavlová. The network helps show where Šárka Pavlová may publish in the future.

Co-authorship network of co-authors of Šárka Pavlová

This figure shows the co-authorship network connecting the top 25 collaborators of Šárka Pavlová. A scholar is included among the top collaborators of Šárka Pavlová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Šárka Pavlová. Šárka Pavlová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 8
2 2
3 0
4 3
5 14
6 24
7 22
8 6
9 8
10 1
11 49
12 17
13 52
14 82
15 26
16 30
17 6
18 29
19 6
20 10

About Šárka Pavlová

Šárka Pavlová is a scholar working on Genetics, Oncology and Immunology, having authored 42 papers that have together received 854 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (25 papers), Cancer-related Molecular Pathways (16 papers) and Lymphoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Genetics (342 citations), Cancer Research (161 citations) and Pathology and Forensic Medicine (190 citations). Šárka Pavlová has collaborated with scholars based in Czechia, Germany and Sweden. Frequent co-authors include Šárka Pospı́šilová, Karla Plevová, Jana Šmardová, Yvona Brychtová, Michael Doubek, Boris Tichý, Jitka Malčíková, Jiřı́ Mayer, Martin Trbušek and Kateřina Staňo Kozubík. Their work appears in journals such as Blood, Cancer Research and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026